Hodgkin's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Hodgkin's Disease, including details on causes, cancer, lymphoma, stages, symptoms.

Volume 8 (2011), Issue 5 (May)

1. Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis.
   PLoS One, 6(4): e18856. [Abstract] [Full-text]
2. ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II.
   J Am Coll Radiol, 8(5): 302-8. [Abstract] [Full-text]
3. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma.
   Clin Cancer Res, 17(9): 2885-92. [Abstract] [Full-text]
4. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
   Ann Hematol, 90(6): 685-91. [Abstract] [Full-text]
5. Pediatric Hodgkin Lymphoma: CT features at presentation, on treatment and its prognostic significance.
   Indian J Pediatr, 78(5): 549-54. [Abstract] [Full-text]
6. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment.
   J Clin Oncol, 29(14): 1812-26. [Abstract] [Full-text]
7. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma.
   Int J Radiat Oncol Biol Phys, 80(2): 324-32. [Abstract] [Full-text]
8. TSH suppression as a possible means of protection against hypothyroidism after irradiation for childhood Hodgkins lymphoma.
   Pediatr Blood Cancer, 57(1): 166-8. [Abstract] [Full-text]
9. Retrospective evaluation of PET-MRI registration algorithms.
   J Digit Imaging, 24(3): 485-93. [Abstract] [Full-text]
10. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.
    Eur J Nucl Med Mol Imaging, 38(6): 1064-71. [Abstract] [Full-text]
11. Aberrant cytoplasmic expression of cyclin B1 protein and its correlation with EBV-LMP1, P53 and P16(INK4A) in classical Hodgkin lymphoma in China.
    Pathol Oncol Res, 17(2): 369-73. [Abstract] [Full-text]
12. Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma.
    Clin Cancer Res, 17(10): 3443-54. [Abstract] [Full-text]
13. Germinal center-specific protein human germinal center associated lymphoma directly interacts with both myosin and actin and increases the binding of myosin to actin.
    FEBS J, 278(11): 1922-31. [Abstract] [Full-text]
14. Bilateral phrenic nerve dysfunction: a late complication of mantle radiation.
    J Neurooncol, 103(2): 393-5. [Abstract] [Full-text]
15. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
    Blood, 117(20): 5314-20. [Abstract] [Full-text]
16. Neurological presentation of Hodgkin lymphoma in the Italian Association of Pediatric Hematology and Oncology LH-2004 protocol.
    Leuk Lymphoma, 52(6): 1049-54. [Abstract] [Full-text]
17. Extensive radiation-induced heart disease in an adult patient treated for lymphoma as a child.
    Can J Cardiol, 27(3): 390.e1-4. [Abstract] [Full-text]
18. Current concepts and controversies in the management of early stage Hodgkin lymphoma.
    Leuk Lymphoma, 52(6): 962-71. [Abstract] [Full-text]
19. Interobserver variability of clinical target volume delineation in supra-diaphragmatic Hodgkin's disease: a multi-institutional experience.
    Strahlenther Onkol, 187(6): 357-66. [Abstract] [Full-text]
20. Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease.
    Cancer Treat Rev, 37(5): 391-403. [Abstract] [Full-text]
21. Rituximab in Hodgkin lymphoma: is the target always a hit?
    Cancer Treat Rev, 37(5): 385-90. [Abstract] [Full-text]
22. Coregistration of prechemotherapy PET-CT for planning pediatric Hodgkin's disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition.
    Int J Radiat Oncol Biol Phys, 80(3): 793-9. [Abstract] [Full-text]

© 2004-2012 Hodgkin's Disease Research Today. All Rights Reserved.